Biomarker Detection for MIS-C Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing Multisystem Inflammatory Syndrome in Children (MIS-C) and severe acute COVID-19 are insensitive, leading to delayed effective therapy due to limited sensitivity in detecting these conditions, particularly in pediatric populations.
Innovation Solution
The use of specific biomarkers such as Fc gamma binding protein (FCGBP), Mannose receptor C-type 1 (MRC1), and LPS binding protein (LBP) in blood samples for early and sensitive detection through ELISA methods, along with antibodies for diagnosing and treating MIS-C and severe acute COVID-19.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used for MIS-C and severe acute COVID-19, then the diagnostic process is simple and straightforward, but the sensitivity is limited leading to delayed diagnosis
Solution Approach 1:
The diagnostic approach is segmented into multiple independent biomarker detections (FCGBP, MRC1, LBP, and other cytokines) rather than relying on a single test. This segmentation allows each biomarker to be measured with high sensitivity while collectively providing comprehensive diagnostic coverage, resolving the contradiction between sensitivity and complexity by dividing the diagnostic task into manageable molecular components.
Solution Approach 2:
The invention changes the measurement parameters by detecting specific protein biomarkers at the molecular level rather than using conventional clinical parameters. By measuring biomarker concentrations (e.g., FCGBP, MRC1, LBP) with high-sensitivity assays, the diagnostic precision is dramatically improved while the complexity is managed through standardized laboratory protocols.
2Reliability
If early and accurate diagnosis of MIS-C is achieved through biomarker detection, then patient outcomes are improved and multiorgan failure is reduced, but the diagnostic timing and treatment urgency increase pressure on the system
Solution Approach 1:
The biomarker panel is designed to detect early inflammatory responses before full-blown MIS-C syndrome develops. By measuring biomarkers like FCGBP, MRC1, and LBP that appear early in the disease process, the system enables preliminary identification of at-risk patients, allowing intervention before multiorgan failure occurs, thus improving reliability while minimizing time loss.
Solution Approach 2:
The diagnostic system provides rapid feedback through biomarker level measurements, enabling clinicians to quickly assess disease severity and respond appropriately. The quantitative biomarker data creates a feedback loop that guides treatment decisions, improving patient outcomes while reducing diagnostic uncertainty and associated time delays.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables early and accurate diagnosis and treatment of MIS-C and severe acute COVID-19 by identifying biomarkers indicative of the conditions, improving patient outcomes and reducing the risk of multiorgan failure.
Implementation Method 1
detecting at least one biomarker (e.g., Fc gamma binding protein (FCGBP); Mannose receptor C-type 1 (MRC1); LPS binding protein (LBP)) in a sample from a subject
Data Source
AI summary
Embodiments disclosed here are directed to novel methods for diagnosing MIS-C or severe acute COVID-19, by detecting a biomarker in a blood sample from a subject suspected of or suffering from MIS-C or severe acute COVID-19, where the methods are for early detection or diagnosis of MIS-C or severe acute COVID-19. Also, disclosed are embodiments directed to apparatuses for use with the novel methods described here. Methods of detecting at least one biomarker and/or diagnosing MIS-C or severe acute COVID-19 disease in a pediatric subject suspected from suffering MIS-C or severe acute COVID-19 that can be used in combination with methods of treating a subject suspected of or suffering from MIS-C or severe acute COVID-19, accelerates the diagnosis and treatment, and improves prognosis.